Literature DB >> 2893187

Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.

F de Wolf1, J M Lange, J Goudsmit, P Cload, J de Gans, P T Schellekens, R A Coutinho, A P Fiddian, J van der Noordaa.   

Abstract

18 men with longstanding human immunodeficiency virus (HIV) antigenaemia but no symptoms received zidovudine in low-dose regimens (250 mg 6-hourly, 500 mg 6-hourly, or 500 mg 12-hourly) with or without acyclovir. Serum HIV antigen rose in only 1 patient and declined significantly in 13 (to below cut-off values in 9). In the 1 subject from whom HIV antigen positive cerebrospinal fluid was obtained, the fluid was antigen negative after 12 weeks of treatment. Acyclovir treatment alone or in addition did not seem to influence serum antigen levels. In 7 untreated men serum antigen levels rose or remained stable during follow-up. CD4+ cell counts increased in 14/18 treated subjects and 1/7 untreated subjects. No disease progression was observed in either group. Regression of enlarged lymph nodes was seen in the zidovudine-treated subjects. Adverse reactions to the study drugs were infrequent and mild. Anaemia caused symptoms in 2, but serious leucopenia or neutropenia was not observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893187     DOI: 10.1016/s0140-6736(88)91179-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Needlestick injuries among resident physicians.

Authors:  A E Heald; D F Ransohoff
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Improved detection of HIV p24 antigen in serum after acid pretreatment.

Authors:  M A Rodríguez-Iglesias; J R Alvarez; A Vergara; M S Garcia-Valdivia; I Jesús; J Mira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 3.  The ethics of screening for early intervention in HIV disease.

Authors:  C Levine; R Bayer
Journal:  Am J Public Health       Date:  1989-12       Impact factor: 9.308

4.  Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment.

Authors:  J W Mulder; P Krijnen; R A Coutinho; M Bakker; J Goudsmit; J M Lange
Journal:  Genitourin Med       Date:  1991-06

Review 5.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 6.  AIDS and the lung. 2--Antiretroviral treatment in human immunodeficiency virus disease.

Authors:  A J Pinching
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

7.  Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

Authors:  P Portegies; J de Gans; J M Lange; M M Derix; H Speelman; M Bakker; S A Danner; J Goudsmit
Journal:  BMJ       Date:  1989-09-30

Review 8.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

Authors:  M D de Jong; J Veenstra; N I Stilianakis; R Schuurman; J M Lange; R J de Boer; C A Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  Molecular specificity of two commercial enzyme linked immunosorbent assays for human immunodeficiency virus antigens.

Authors:  K E Brown; D C Shanson; P Mascagni; A R Coates
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.